Document is current
Any future updates will be listed below
-
Authors
Mercan, Caner https://orcid.org/0000-0003-1913-4669
Balkenhol, Maschenka
Salgado, Roberto https://orcid.org/0000-0002-1110-3801
Sherman, Mark https://orcid.org/0000-0002-9222-8808
Vielh, Philippe
Vreuls, Willem
Polónia, António
Horlings, Hugo M. https://orcid.org/0000-0003-4782-8828
Weichert, Wilko
Carter, Jodi M.
Bult, Peter
Christgen, Matthias
Denkert, Carsten https://orcid.org/0000-0002-2249-0982
van de Vijver, Koen https://orcid.org/0000-0002-2026-9790
Bokhorst, John-Melle
van der Laak, Jeroen https://orcid.org/0000-0001-7982-0754
Ciompi, Francesco https://orcid.org/0000-0001-8327-9606
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (825292, 825292)
- License Information
-
More Information
Article History
Received: 23 September 2021
Accepted: 21 October 2022
First Online: 8 November 2022
Competing interests
: The authors declare the following competing financial interests. C.M. received research funding from Philips, NWO-Perspectief program EDL (Efficient Deep Learning), the Netherlands, and ExaMode in the last 5 years. J.v.d.L. was a member of the advisory boards of Philips, the Netherlands and ContextVision, Sweden, and received research funding from Philips, the Netherlands, ContextVision, Sweden, and Sectra, Sweden in the last 5 years. He is chief scientific officer (CSO) and shareholder of Aiosyn BV, the Netherlands. F.C. was Chair of the Scientific and Medical Advisory Board of TRIBVN Healthcare, France, and received advisory board fees from TRIBVN Healthcare, France in the last 5 years. He is shareholder of Aiosyn BV, the Netherlands. R.S. reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and advisory board fees for Bristol Myers Squibb; and personal fees from Roche for an advisory board related to a trial-research project. W.W. receives research funding from Roche, MSD, BMS, Roche, and AstraZeneca. C.D. is a member of the advisory boards of MSD Oncology, Daiichi Sankyo, Molecular Health, AstraZeneca, Merck, and receives research funding from Myriad Genetics and Roche. All other authors declare no competing financial or non-financial interests.
